Parnax Lab [PARNAXLAB] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison

Parnax Lab Ltd.

BSE
Loading...

Sun Pharmaceutical Industries Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Parnax Lab Ltd. wins in 8 metrics, Sun Pharmaceutical Industries Ltd. wins in 11 metrics, with 0 ties. Sun Pharmaceutical Industries Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Parnax Lab Ltd. Sun Pharmaceutical Industries Ltd. Better
P/E Ratio (TTM) 14.43 36.73 Parnax Lab Ltd.
Price-to-Book Ratio 2.01 5.15 Parnax Lab Ltd.
Debt-to-Equity Ratio 76.46 6.68 Sun Pharmaceutical Industries Ltd.
PEG Ratio 0.12 3.59 Parnax Lab Ltd.
EV/EBITDA 9.07 23.61 Parnax Lab Ltd.
Profit Margin (TTM) 5.49% 19.21% Sun Pharmaceutical Industries Ltd.
Operating Margin (TTM) 7.77% 26.17% Sun Pharmaceutical Industries Ltd.
EBITDA Margin (TTM) 7.77% 26.17% Sun Pharmaceutical Industries Ltd.
Return on Equity 13.84% 15.08% Sun Pharmaceutical Industries Ltd.
Return on Assets (TTM) 6.07% 11.87% Sun Pharmaceutical Industries Ltd.
Free Cash Flow (TTM) $137.24M $119.44B Sun Pharmaceutical Industries Ltd.
Dividend Yield N/A 0.97% N/A
1-Year Return 31.91% 7.25% Parnax Lab Ltd.
Price-to-Sales Ratio (TTM) 0.79 7.05 Parnax Lab Ltd.
Enterprise Value $2.50B $3,783.37B Sun Pharmaceutical Industries Ltd.
EV/Revenue Ratio 1.10 6.66 Parnax Lab Ltd.
Gross Profit Margin (TTM) 40.69% 80.96% Sun Pharmaceutical Industries Ltd.
Revenue per Share (TTM) $198 $237 Sun Pharmaceutical Industries Ltd.
Earnings per Share (Diluted) $10.90 $45.46 Sun Pharmaceutical Industries Ltd.
Beta (Stock Volatility) 0.01 0.11 Parnax Lab Ltd.

Parnax Lab Ltd. vs Sun Pharmaceutical Industries Ltd. Stock Performance Analysis

Loading Price Chart...

PARNAXLAB
SUNPHARMA

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Parnax Lab Ltd.3.49%-17.74%-24.75%-4.21%3.00%-6.06%
Sun Pharmaceutical Industries Ltd.-0.08%-2.77%-1.84%2.13%-0.53%4.00%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Parnax Lab Ltd.31.91%128.43%395.49%362.62%35.18%1,601.79%
Sun Pharmaceutical Industries Ltd.7.25%79.99%166.96%144.01%669.48%2,278.32%

Performance & Financial Health Analysis: Parnax Lab Ltd. vs Sun Pharmaceutical Industries Ltd.

MetricPARNAXLABSUNPHARMA
Market Information
Market Cap i₹1.81B₹3.88T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i7,6663,903,142
90 Day Avg. Volume i6,2283,253,866
Last Close₹126.00₹1,788.50
52 Week Range₹96.25 - ₹182.00₹1,548.00 - ₹1,916.60
% from 52W High-30.77%-6.68%
All-Time High₹193.50 (Nov 04, 2024)₹1,960.35 (Sep 30, 2024)
% from All-Time High-34.88%-8.77%
Growth Metrics
Quarterly Revenue Growth0.57%0.14%
Quarterly Earnings Growth1.24%0.16%
Financial Health
Profit Margin (TTM) i0.05%0.19%
Operating Margin (TTM) i0.08%0.26%
Return on Equity (TTM) i0.14%0.15%
Debt to Equity (MRQ) i76.466.68
Cash & Liquidity
Book Value per Share (MRQ)₹78.10₹324.46
Cash per Share (MRQ)₹1.79₹115.87
Operating Cash Flow (TTM) i₹297.41M₹110.84B
Levered Free Cash Flow (TTM) i₹115.19M₹109.29B
Dividends
Last 12-Month Dividend Yield iN/A0.97%
Last 12-Month Dividend iN/A₹16.50

Valuation & Enterprise Metrics Analysis: Parnax Lab Ltd. vs Sun Pharmaceutical Industries Ltd.

MetricPARNAXLAB (Apr 24, 2026)SUNPHARMA (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i14.4336.73
Forward P/E iN/A29.48
PEG Ratio i0.123.59
Price to Sales (TTM) i0.797.05
Price to Book (MRQ) i2.015.15
Market Capitalization
Market Capitalization i₹1.81B₹3.88T
Enterprise Value i₹2.50B₹3.78T
Enterprise Value Metrics
Enterprise to Revenue i1.106.66
Enterprise to EBITDA i9.0723.61
Risk & Other Metrics
Beta i0.010.11
Book Value per Share (MRQ) i₹78.10₹324.46

Financial Statements Comparison: Parnax Lab Ltd. vs Sun Pharmaceutical Industries Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPARNAXLAB (2025)SUNPHARMA (2025)
Revenue/Sales i1.88B520.41B
Cost of Goods Sold i1.25B121.98B
COGS % of Revenue i66.6%23.4%
Gross Profit i627.22M398.44B
Gross Margin i33.4%76.6%
Research & Development i17.49MN/A
Operating Income (EBIT) i197.88M125.81B
Operating Margin i10.5%24.2%
EBITDA i285.44M167.25B
EBITDA Margin i15.2%32.1%
Pre-Tax Income i156.74M137.52B
Pre-Tax Income % of Revenue i8.3%26.4%
Income Tax i41.35M27.72B
Income Tax % of Revenue i2.2%5.3%
Net Income (Profit) i115.39M109.65B
Profit Margin i6.1%21.1%

Balance Sheet & Liquidity Metrics

MetricPARNAXLAB (2025)SUNPHARMA (2025)
Cash & Equivalents i5.50M102.69B
Total Current Assets i683.40M526.24B
Total Current Assets % of Revenue i36.4%101.1%
Total Current Liabilities i743.34M181.94B
Total Current Liabilities % of Revenue i39.6%35.0%
Long-Term Debt i262.42M3.58B
Long-Term Debt % of Revenue i14.0%0.7%
Total Shareholders Equity i832.42M724.86B
Retained Earnings i554.20M578.62B
Retained Earnings % of Revenue i29.5%111.2%
Property, Plant & Equipment i292.67M100.36B

Cash Flow Statement Comparison

MetricPARNAXLAB (2025)SUNPHARMA (2025)
Operating Cash Flow i297.41M110.84B
Operating Cash Flow % of Revenue i15.8%21.3%
Capital Expenditures i-70.38M-20.68B
Free Cash Flow i137.24M119.44B
FCF Margin i7.3%23.0%
Debt Repayment i-104.25M-43.44B
Common Stock Repurchase iN/A-29.00B

Short Interest & Institutional Ownership Analysis

MetricPARNAXLABSUNPHARMA
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i11.49M2.40B
Float Shares i2.99M1.07B
% Held by Insiders i73.92%55.62%
% Held by Institutions i0.00%28.69%
% Held by Public i26.08%15.69%

Dividend Analysis & Yield Comparison: Parnax Lab Ltd. vs Sun Pharmaceutical Industries Ltd.

MetricPARNAXLABSUNPHARMA
Last 12-Month Dividend iN/A₹16.50
Last 12-Month Dividend Yield iN/A0.97%
3-Year Avg Annual Dividend iN/A₹17.33
3-Year Avg Dividend Yield iN/A0.51%
3-Year Total Dividends iN/A₹52.00
Ex-Dividend DateN/AFeb 05, 2026